Deregulated NF-kappa B activity in haematological malignancies

[en] The NF-kappa B family of transcription factors plays key roles in the control of cell proliferation and apoptosis. Constitutive NF-kappa B activation is a common feature for most haematological malignancies and is therefore believed to be a crucial event for enhanced proliferation and survival of these malignant cells. In this review, we will describe the molecular mechanisms underlying NF-kappa B deregulation in haematological malignancies and will highlight what is still unclear in this field, 20 years after the discovery of this transcription factor. (c) 2006 Elsevier Inc. All rights reserved.

Research Center/Unit :

Giga-Signal Transduction - ULiège

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Keutgens, Aurore ; Université de Liège - ULiège > Chimie médicale

Robert, Isabelle ; Université de Liège - ULiège > Chimie médicale

Viatour, Patrick ; Université de Liège - ULiège > Chimie médicale

Chariot, Alain ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Language :

English

Title :

Deregulated NF-kappa B activity in haematological malignancies

Publication date :

30 October 2006

Journal title :

Biochemical Pharmacology

ISSN :

0006-2952

eISSN :

1873-2968

Publisher :

Pergamon-Elsevier Science Ltd, Oxford, United Kingdom

Volume :

Issue :

Pages :

1069-1080

Peer reviewed :

Peer Reviewed verified by ORBi

Name of the research project :

Insight into the oncogenic potential of BCL-3

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique
Télévie
Belgian Foundation Against Cancer
ULg. ARC - Université de Liège. Actions de Recherche Concertées

Funding text :

This work was supported by grants from the Concerted Research Action Program (University of Liege), the F.N.R.S., TELEVIE, the Belgian Federation against Cancer, the ‘‘Centre Anti-Cancereux’’ and the ‘‘Leon Fredericq’’ Fundation (University of Liege).

Available on ORBi :

since 06 January 2009

Statistics

Number of views

78 (12 by ULiège)

Number of downloads

276 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev 18 (2004) 2195-2224
Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
Bonizzi G., and Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 (2004) 280-288
Rothwarf D.M., Zandi E., Natoli G., and Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395 (1998) 297-300
Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93 (1998) 1231-1240
Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris M., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17 (2002) 525-535
Claudio E., Brown K., Park S., Wang H., and Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3 (2002) 958-965
Coope H.J., Atkinson P.G., Huhse B., Belich M., Janzen J., Holman M.J., et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 21 (2002) 5375-5385
Siebenlist U., Brown K., and Claudio E. Control of lymphocyte development by nuclear factor-κB. Nat Rev Immunol 5 (2005) 435-442
Grossmann M., Metcalf D., Merryfull J., Beg A., Baltimore D., and Gerondakis. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci 96 (1999) 11848-11853
Voll R.E., Jimi E., Phillips R.J., Barber D.F., Rincon M., Hayday A.C., et al. NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity 13 (2000) 677-689
Feng B., Cheng S., Pear W.S., and Liou H.C. NF-κB inhibitor blocks B cell development at two checkpoints. Med Immunol 3 (2004) 1
Schmidt-Supprian M., Courtois G., Tian J., Coyle A.J., Israel A., and Rajewsky K. Mature T cells depend on signaling through the IKK complex. Immunity 19 (2003) 377-389
Pasparakis M., Schmidt-Supprian M., and Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med 196 (2002) 743-752
Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5 (2005) 749-759
Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2 (2002) 725-734
Stoffel A. The NF-κB signalling pathway: a therapeutic target in lymphoid malignancies. Expert Opin Ther Targets 9 (2005) 1045-1061
Shaffer A.L., Rosenwald, and Staudt L.M. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2 (2002) 920-932
Sanchez-Beato M., Saez A.I., Navas I.C., Algara P., Sol Mateo M., Villuendas R., et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 59 (2001) 205-213
Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10, 1419-32.
Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC press pp. 120-127
Lu D., Thompson J.D., Gorski G.K., Rice N.R., Mayer M.G., and Yunis J.J. Alterations at the rel locus in human lymphoma. Oncogene 6 (1991) 1235-1241
Heckman C.A., Mehew J.W., and Boxer L.M. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21 (2002) 3898-3908
Heckman C.A., Cao T., Somsouk L., Duan H., Mehew J.W., Zhang C.Y., et al. Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 63 (2003) 6666-6673
Rao P.H., Houldsworth J., Dyomina K., Parsa N.Z., Cigudosa J.C., Louie D.C., et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92 (1998) 234-240
Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. Constitutive nuclear factor κB activity is required for survival of Activated B Cell-like Diffuse Large B Cell Lymphoma cells. J Exp Med 194 (2001) 1861-1874
Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441 (2006) 106-110
Feuerhake F., Kutok J.L., Monti S., Chen W., LaCasce A.S., Cattoretti G., et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106 (2005) 1392-1399
Ye H., Liu H., Attygalle A., Wotherspoon A.C., Nicholson A.G., Charlotte F., et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 102 (2003) 1012-1018
Willis T.G., Jadayel D.M., Du M.Q., Peng H., Perry A.R., Abdul-Rauf M., et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96 (1999) 35-45
Zhang Q., Siebert R., Yan M., Hinzmann B., Cui X., Xue L., et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 22 (1999) 63-68
Ruland J., Duncan G.S., Elia A., del Barco Barrantes I., Nguyen L., Plyte S., et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 104 (2001) 33-42
Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M., et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427 (2004) 167-171
Zhou H., Du M.Q., and Dixit V.M. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7 (2005) 425-431
Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., and Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171 (2003) 88-95
Ni H., Ergin M., Huang Q., Qin J.Z., Amin H.M., Martinez R.L., et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115 (2001) 279-286
Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood; in press.
Martinez-Delgado B., Cuadros M., Honrado E., Ruiz de la Parte A., Roncador G., Alves J., et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 19 (2005) 2254-2263
Neri A., Chang C.C., Lombardi L., Salina M., Corradini P., Maiolo A.T., et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell 67 (1991) 1075-1087
Chang C.C., Zhang J., Lombardi L., Neri A., and Dalla-Favera R. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol cell Biol 15 (1995) 180-187
Mathas S., Johrens K., Joos S., Lietz A., Hummel F., Janz M., et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 106 (2005) 4287-4293
McKeithan T.W., Rowley J.D., Shows T.B., and Diaz M.O. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukaemia. Proc Natl Acad Sci USA 84 (1987) 9257-9260
Ohno H., Takimoto G., and McKeithan T.W. The candidate proto-oncogene BCL-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60 (1990) 991-999
Nishikori M., Maesako Y., Ueda C., Kurata M., Uchiyama T., and Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 101 (2003) 2789-2796
Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., et al. The oncoprotein BCL-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 72 (1993) 729-739
Viatour P., Dejardin E., Warnier M., Lair F., Claudio E., Bureau F., et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 16 (2004) 35-45
Rebollo A., Dumoutier L., Renauld J.C., Zaballos A., Avllon V., and Martinez-A C. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol 20 (2000) 3407-3416
Mitchell T.C., Hildeman D., Kedl R.M., Teague T.K., Schaefer B.C., White J., et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol 2 (2001) 397-402
Kashatus D., Cogswell P., and Baldwin A.S. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 20 (2006) 225-235
Staudt L. The molecular and cellular origins of Hodgkin's disease. J Exp Med 191 (2000) 207-212
Thomas R.K., Re D., Wolf J., and Diehl V. Part I. Hodgkins'lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 5 (2004) 11-18
Bargou R.C., Leng C., Krappmann D., Emmerich F., Mapara M.Y., Bommert K., et al. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 (1996) 4340-4347
Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 (1997) 2961-2969
Hinz M., Löser P., Mathas S., Krappmann D., Dörken B., and Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97 (2001) 2798-2807
Hinz M., Lemke P., Anagnostopoulos I., Hacker C., Krappmann D., Mathas S., et al. Nuclear Factor kB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196 (2002) 605-617
Cabannes E., Khan G., Aillet F., Jarrett R.F., and Hay R.T. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18 (1999) 3063-3070
Emmerich F., Meiser M., Hummel M., Demel G., Foss H.-D., Jundt F., et al. Overexpression of I Kappa B Alpha without inhibition Of NF-κB activity and mutations in the I Kappa B Alpha gene in Reed-Sternberg cells. Blood 94 (1999) 3129-3134
Jungnickel B., Staratschek-Jox A., Bräuninger A., Spieker T., Wolf J., Diehl V., et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 191 (2000) 395-402
Emmerich F., Theurich S., Hummel M., Haeffker A., Vry M.S., Döhner K., et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 201 (2003) 413-420
Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dörken B., and Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18 (1999) 943-953
Jundt F., Anagnostopoulos I., Förster R., Mathas S., Stein H., and Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99 (2002) 3398-3403
Clodi K., and Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 27 (1997) 195-205
Horie R., Watanabe T., Morishita Y., Ito K., Ishida T., Kanegae Y., et al. Ligand-independent signalling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21 (2002) 2493-2503
Weiss L.M., Strickler J.G., Warnke R.A., Purtilo D.T., and Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 129 (1987) 86-91
Sylla B.S., Hung S.C., Davidson D.M., Hatzivassiliou E., Malinin N.L., Wallach D., et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci USA 95 (1998) 10106-10111
Luftig M., Yasui T., Soni V., Kang M.S., Jacobson N., Cahir-McFarland E., et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci USA 101 (2004) 141-146
Mathas S., Hinz M., Anagnostopoulos I., Krappmann D., Lietz A., Jundt F., et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J 21 (2002) 4104-4113
Kordes U., Krappmann D., Heissmeyer V., Ludwig W.D., and Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14 (2000) 399-402
Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood 98 (2001) 2301-2307
Baumgartner B., Weber M., Quirling M., Fischer C., Page S., Adam M., et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 16 (2002) 2062-2071
Bueso-Ramos C.E., Rocha F.C., Shishodia S., Medeiros L.J., Kantarjian H.M., Vadhan-Raj S., et al. Expression of constitutively active nuclear-κB RelA transcription factor in blasts of acute myeloid leukaemia. Hum Pathol 35 (2003) 246-253
Frelin C., Imbert V., Griessinger E., Peyron A.C., Rochet N., Philip P., et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukaemia cells. Blood 105 (2005) 804-811
Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352 (2005) 804-815
Romano M.F., Lamberti A., and Tassone P. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92 (1998) 990-995
Furman R.R., Asgary Z., Mascarenhas J.O., Liou H.C., and Schattner E.J. Modulation of NF-κB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164 (2000) 2200-2206
Munzert G., Kirchner D., Stobbe H., Bergmann L., Schmid R.M., Döhner H., et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukaemia: analysis of NF-κB/Rel-regulated inhibitors of apoptosis. Blood 100 (2002) 3749-3756
Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., and Baldwin Jr. A.S. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12 (1998) 968-981
Kirchner D., Duyster J., Ottmann O., Schmid R.M., Bergmann L., and Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappB/Rel activation. Exp Hematol 31 (2003) 504-511
Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107 (2006) 1156-1165
Rayet B., and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
Abbadie C., Kabrun N., Bouali F., Smardova J., Stehelin D., Vandenbunder B., et al. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 75 (1993) 899-912
Chu Z.L., Shin Y.A., Yang J.M., DiDonato J.A., and Ballard D.W. IKK gamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukaemia virus type 1. J Biol Chem 274 (1999) 15297-15300
Harbay E.W., and Sun S.C. IKK gamma serves as a docking dubunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukaemia virus Tax protein. J Biol Chem 274 (1999) 22911-22914
Lamsoul I., Lodewick J., Lebrun S., Brasseur R., Burny A., Gaynor R., et al. Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-κB activation by the human T-cell leukaemia virus Tax oncoprotein. Mol Cell Biol 25 (2005) 10391-10406
Xiao G., Cvijic M.E., Fong A., Harhaj E.W., Uhlik M.T., Waterfield M., et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J 20 (2001) 6805-6815
Perkins N.D. NF-κB: tumor promoter or suppressor?. Trends Cell Biol 14 (2004) 64-69
Weil R., and Israël A. Deciphering the pathway from the TCR to NF-κB. Cell Death Differ 13 (2006) 826-833
Derudder E., Laferte A., Ferreira V., Mishal Z., Baud V., Tarantino N., et al. Identification and characterization of p100HB, a new mutant form of p100/NF-kappa B2. Biochem Biophys Res Commun 308 (2003) 744-749
Zhang J., Chang C.C., Lombardi L., and Dalla-Favera R. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 9 (1994) 1931-1937
Thakur S., Lin J.C., Tseng W.T., Kumar S., Bravo R., Foss F., et al. Rearrangement and altered expression of the NFKB2 gene in human cutaneous T-lymphoma cells. Oncogene 9 (1994) 2335-2344
Migliazza A., Lombardi L., Rocchi M., Trecca D., Chang C.C., Antonacci R., et al. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood 84 (1994) 3850-3860